Luvadaxistat Development Halted Due to Study Failure
- Neurocrine Biosciences’s schizophrenia treatment trial fails to meet primary endpoint
- Large variability and imbalance in baseline characteristics led to study failure
- Company halts development of luvadaxistat, shifts focus to other treatments
Neurocrine Biosciences announced that its trial of luvadaxistat as a potential treatment for cognitive impairment in schizophrenia patients did not achieve its primary endpoint. The company cited large variability in cognitive measures and imbalance in baseline characteristics among subjects as reasons for the failure. As a result, Chief Medical Officer Eiry Roberts stated that Neurocrine will cease development of luvadaxistat and redirect efforts towards other potential treatments for schizophrenia and major depressive disorder. Shares fell 2.3% to $118.50 in after-hours trading.
Factuality Level: 9
Factuality Justification: The article provides accurate and objective information about the trial results of luvadaxistat for cognitive impairment in schizophrenia, the reasons behind the failure, and the company’s decision to halt further development. It also includes relevant financial information about the stock price.
Noise Level: 4
Noise Justification: The article provides relevant information about the failure of a clinical trial and the company’s decision to halt further development of luvadaxistat. It also mentions the reason for the failure and the company’s plan to focus on other treatments. However, it could provide more context or analysis on the implications of this news for the industry or future research in schizophrenia treatment.
Public Companies: Neurocrine Biosciences (NBIX)
Key People: Eiry Roberts (Chief Medical Officer)
Financial Relevance: Yes
Financial Markets Impacted: Neurocrine Biosciences stock
Financial Rating Justification: The article discusses the failure of a clinical trial for a potential treatment and its impact on the company’s focus, which affects the company’s stock price.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the text.
Move Size: The market move size mentioned in the article is -2.3%.
Sector: Healthcare
Direction: Down
Magnitude: Small
Affected Instruments: Stocks
www.marketwatch.com 
